Cabergoline
- Generic Name
- Cabergoline
- Brand Names
- Dostinex
- Drug Type
- Small Molecule
- Chemical Formula
- C26H37N5O2
- CAS Number
- 81409-90-7
- Unique Ingredient Identifier
- LL60K9J05T
- Background
Cabergoline, an ergot derivative, is a long-acting dopamine agonist and prolactin inhibitor. It is used to treat hyperprolactinemic disorders and Parkinsonian Syndrome. Cabergoline possesses potent agonist activity on dopamine D2 receptors.
- Indication
For the treatment of hyperprolactinemic disorders, either idiopathic or due to prolactinoma (prolactin-secreting adenomas). May also be used to manage symptoms of Parkinsonian Syndrome as monotherapy during initial symptomatic management or as an adjunct to levodopa therapy during advanced stages of disease.
- Associated Conditions
- Hyperprolactinemia, Idiopathic hyperprolactinemic disorder
- Associated Therapies
- Inhibition of physiological lactation
Pharmacological Inhibition of Lactation After 16 to 20 Week Abortion
- Conditions
- Interventions
- First Posted Date
- 2023-11-08
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 200
- Registration Number
- NCT06123026
- Locations
- 🇺🇸
Northwestern Medical Center, Chicago, Illinois, United States
Lactation Inhibition, the Efficiency of Vitamin B6 Versus Cabergoline
- First Posted Date
- 2021-08-27
- Last Posted Date
- 2022-11-14
- Lead Sponsor
- HaEmek Medical Center, Israel
- Target Recruit Count
- 89
- Registration Number
- NCT05024422
- Locations
- 🇮🇱
HaEmek Medical Center, Afula, Israel
Satisfaction of Patients With the Chosen Method of Inhibition of Lactation
- Conditions
- Interventions
- First Posted Date
- 2019-07-31
- Last Posted Date
- 2019-07-31
- Lead Sponsor
- Żelazna Medical Centre, LLC
- Target Recruit Count
- 90
- Registration Number
- NCT04038749
- Locations
- 🇵🇱
Żelazna Medical Centre, Warsaw, Poland
Comparison of Treatment Outcome of Cabergoline According to Target Prolactin Levels in Patients With Prolactinoma
- Conditions
- Interventions
- First Posted Date
- 2018-03-07
- Last Posted Date
- 2020-03-18
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 68
- Registration Number
- NCT03457389
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
Co-administration of Cabergoline and Gliclazide Improve Glycemic Parameters and Lipid Profile in T2DM Patients
- First Posted Date
- 2017-10-18
- Last Posted Date
- 2018-08-27
- Lead Sponsor
- Sherief Abd-Elsalam
- Target Recruit Count
- 60
- Registration Number
- NCT03313661
- Locations
- 🇪🇬
Sherief Abd-Elsalam, Cairo, Egypt
Cabergoline in Nonfunctioning Pituitary Adenomas
- Conditions
- Interventions
- First Posted Date
- 2017-09-05
- Last Posted Date
- 2017-09-07
- Lead Sponsor
- University of Sao Paulo General Hospital
- Target Recruit Count
- 140
- Registration Number
- NCT03271918
- Locations
- 🇧🇷
Laboratorio de Investigacoes Medicas 25, São Paulo, SP, Brazil
Value of Cabergoline and Low Dose Aspirin in Poor Responders Undergoing ICSI-ET With GnRH Agonist Flare-Up-Protocol
- First Posted Date
- 2017-08-28
- Last Posted Date
- 2017-08-28
- Lead Sponsor
- Cairo University
- Target Recruit Count
- 120
- Registration Number
- NCT03263299
- Locations
- 🇪🇬
Kasr Alainy medical school, Cairo, Egypt
Cabergoline Versus Calcium Gluconate Infusion in the Prevention of Ovarian Hyperstimulation Syndrome
- First Posted Date
- 2016-08-23
- Last Posted Date
- 2018-12-27
- Lead Sponsor
- Aljazeera Hospital
- Target Recruit Count
- 170
- Registration Number
- NCT02875587
- Locations
- 🇪🇬
Aljazeera hospital, Giza, Egypt
🇪🇬Riyadh Fertility and Reproductive Health center, Giza, Egypt
Clomiphene Citrate Plus Cabergoline in Treatment of Polycystic Ovary Syndrome
- Conditions
- Interventions
- First Posted Date
- 2015-12-31
- Last Posted Date
- 2016-06-29
- Lead Sponsor
- Woman's Health University Hospital, Egypt
- Target Recruit Count
- 88
- Registration Number
- NCT02644304
- Locations
- 🇪🇬
Assiut university, Assiut, Egypt
Dopamine Receptor Agonist Therapy for Pain Relief in Women Suffering From Endometriosis: A Pilot Study
- First Posted Date
- 2015-09-07
- Last Posted Date
- 2020-02-05
- Lead Sponsor
- Boston Children's Hospital
- Target Recruit Count
- 10
- Registration Number
- NCT02542410
- Locations
- 🇺🇸
Children's Hospital Boston, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.